Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorAgarwal, Neeraj
dc.contributor.authorAzad, Arun
dc.contributor.authorCarles Galceran, Joan
dc.contributor.authorChowdhury, Simon
dc.contributor.authorMcGregor, Bradley
dc.contributor.authorMerseburger, Axel
dc.date.accessioned2022-08-11T06:09:05Z
dc.date.available2022-08-11T06:09:05Z
dc.date.issued2022-03
dc.identifier.citationAgarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, et al. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Futur Oncol. 2022 Mar;18(10):1185-98.
dc.identifier.issn1479-6694
dc.identifier.urihttp://hdl.handle.net/11351/7985
dc.descriptionAtezolizumab; Cabozantinib; Immune checkpoint inhibitor
dc.description.abstractCabozantinib inhibits multiple receptor tyrosine kinases, including the TAM kinase family, and may enhance response to immune checkpoint inhibitors. One cohort of the ongoing phase Ib COSMIC-021 study (NCT03170960) evaluating cabozantinib plus the PD-L1 inhibitor atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue on/after enzalutamide and/or abiraterone treatment for metastatic disease has shown promising efficacy. Here, we describe the rationale and design of a phase III trial of cabozantinib plus atezolizumab versus a second novel hormone therapy (NHT) in patients who have previously received an NHT for mCRPC, metastatic castration-sensitive PC or nonmetastatic CRPC and have measurable visceral disease and/or extrapelvic adenopathy – a population with a significant unmet need for treatment options.
dc.language.isoeng
dc.publisherFuture Medicine
dc.relation.ispartofseriesFuture Oncology;18(10)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPròstata - Càncer - Hormonoteràpia
dc.subjectMetàstasi
dc.subject.meshProstatic Neoplasms, Castration-Resistant
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Agents, Hormonal
dc.titleA phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2217/fon-2021-1096
dc.subject.decsneoplasias prostáticas resistentes a la castración
dc.subject.decs/farmacoterapia
dc.subject.decsantineoplásicos hormonales
dc.relation.publishversionhttps://doi.org/10.2217/fon-2021-1096
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Agarwal N] Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, USA. [Azad A] Peter MacCallum Cancer Centre & Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Chowdhury S] Guy’s, King’s & St. Thomas’ Hospitals, & Sarah Cannon Research Institute, London, UK. [McGregor B] Lank Center of Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. [Merseburger AS] Department of Urology, University Hospital Schleswig-Holstein, Lubeck, Germany
dc.identifier.pmid35034502
dc.identifier.wos000743733200001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record